Email
Print
1. Toxicity Prediction Market- Market Overview
1.1 Definitions and Scope
2. Toxicity Prediction Market- Executive Summary
3. Toxicity Prediction Market- Landscape
3.1 Comparative analysis
3.1.1 Market Share Analysis- Top Companies
3.1.2 Product Benchmarking- Top Companies
3.1.3 Top 5 Financials Analysis
3.1.4 Patent Analysis- Top Companies
3.1.5 Pricing Analysis
4. Toxicity Prediction Market - Startup companies Scenario Premium Premium
4.1 Top startup company Analysis by
4.1.1 Investment
4.1.2 Revenue
4.1.3 Market Shares
4.1.4 Market Size and Application Analysis
4.1.5 Venture Capital and Funding Scenario
5. Toxicity Prediction Market– Industry Market Entry Scenario Premium Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis - Top companies
6. Toxicity Prediction Market- Market Forces
6.1 Market Drivers
6.2 Market Constraints
6.3 Market Opportunities
6.4 Porters five force model
6.4.1 Bargaining power of suppliers
6.4.2 Bargaining powers of customers
6.4.3 Threat of new entrants
6.4.4 Rivalry among existing players
6.4.5 Threat of substitutes
7. Toxicity Prediction Market -Strategic analysis
7.1 Value chain analysis
7.2 Opportunities analysis
7.3 Market life cycle
7.4 Suppliers and distributors Analysis
8. Toxicity Prediction Market – By Testing (Market Size -$Million)
8.1 Vitro Testing
8.2 Vivo Testing
9. Toxicity Prediction Market – By In Silico Models(Market Size -$Million)
9.1 Dose-response and time-response models
9.2 Pharmacokinetic and pharmacodynamic models
9.3 Structural Alerts
9.4 Rule based models
9.5 Others
10. Toxicity Prediction Market – By Computer Aided Drug Discovery (CADD) (Market Size - $Million)
10.1 Ligand-based drug design
10.2 Structure-Based Drug Design
11. Toxicity Prediction Market– By AI in Drug Discovery (Market Size -$Million)
11.1 AI in Drug Design
11.1.1 Predicting 3D Structure of Target Protein
11.1.2 Predicting Drug-Protein Interactions
11.1.3 AI in Determining Drug Activity
11.1.4 Ai in De Novo Drug Design
11.2 AI in Polypharmacology
11.2.1 Designing Bio Specific Drug Molecules
11.2.2 Designing multi target drug molecules
11.3 AI in Chemical Synthesis
11.3.1 AI in Prediction of Reaction Yield
11.3.2 AI in Prediction of Retro Synthesis Pathways
11.3.3 Developing Insights into Reaction Mechanisms
11.3.4 AI in Designing Synthetic Route
11.4 AI in Drug Repurposing
11.4.1 Identification of Therapeutic Target
11.4.2 Prediction of New Therapeutic Use
11.5 AI in Drug Screening
11.5.1 Prediction of Toxicity
11.5.2 Prediction of Bioactivity
11.5.3 Prediction of Physicochemical Property
11.5.4 Identification and Classification of Target Cells
12. Toxicity Prediction Market– By Toxicology Services (Market Size -$Million)
12.1 Multiparametric Toxicity
12.2 Cardiotoxicity
12.3 Neurotoxicity
12.4 Nephrotoxicity
12.5 Hepatotoxicity & Drug-induced Liver Injury (DILI)
12.6 Mitochondrial Toxicity
12.7 Mechanistic Toxicity
12.8 Genotoxicity
12.9 Others
13. Toxicity Prediction Market– By Application (Market Size -$Million)
13.1 Drug Discovery and Development
13.2 Drug Repurposing
13.3 Pharmaceutical
13.4 Clinical Trials
13.5 Others
14. Toxicity Prediction Market - By Geography (Market Size -$Million)
14.1 North America
14.1.1 U.S.
14.1.2 Canada
14.1.3 Mexico
14.2 South America
14.2.1 Brazil
14.2.2 Argentina
14.2.3 Colombia
14.2.4 Chile
14.2.5 Rest of South America
14.3 Europe
14.3.1 U.K
14.3.2 Germany
14.3.3 Italy
14.3.4 France
14.3.5 Russia
14.3.6 Rest of Europe
14.4 Asia Pacific
14.4.1 China
14.4.2 India
14.4.3 Japan
14.4.4 South Korea
14.4.5 Australia & New Zealand
14.4.6 Rest of Asia Pacific
14.5 RoW
14.5.1 Middle East
14.5.2 Africa
15. Toxicity Prediction Market- Entropy
15.1 New Product Launches
15.2 M&A’s, Collaborations, JVs and Partnerships
16. Toxicity Prediction Market- List of Key Companies by Country Premium
17. Toxicity Prediction Market Company Analysis
17.1 Market Share, Company Revenue, Products, M&A, Developments
17.2 Company 1
17.3 Company 2
17.4 Company 3
17.5 Company 4
17.6 Company 5
17.7 Company 6
17.8 Company 7
17.9 Company 8
17.10 Company 9
17.11 Company 10 and more
"*Financials would be provided on a best efforts basis for private companies"